CD274 and gastric cancer: Currently, chemotherapy combined with immunotherapy is the standard first-line treatment for metastatic HER2-negative, programmed cell death ligand 1 (PD-L1)-positive gastric cancers based on the positive results of the CheckMate 649 trial (5).